The cost to taxpayers could be enormous.Sales growth of Zepbound in the U.S. has been constrained by rules that bar Medicare, ...

Oppenheimer has recently initiated Inari Medical Inc (NARI) stock to Outperform rating, as announced on December 17, 2024, according to Finviz. Earlier, on September 18, 2024, Stifel had initiated the ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Truist has recently initiated Solid Biosciences Inc (SLDB) stock to Buy rating, as announced on Today, according to Finviz. Earlier, on December 13, 2024, Wedbush had initiated the stock to Outperform ...

Everence Capital Management Inc. bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 7.Stay Ahead of the ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...